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Abstract Alemtuzumab is a humanized monoclonal anti-
body against CD52 and causes depletion of T and B lym-
phocytes, monocytes, and NK cells. Alemtuzumab is
registered for the treatment of multiple sclerosis (MS) and
is also used in chronic lymphocytic leukemia (CLL).
Alemtuzumab is used off-label in kidney transplantation as
induction and anti-rejection therapy. The objective of this
review is to present a review of the pharmacokinetics,
pharmacodynamics, and use of alemtuzumab in kidney
transplantation. A systematic literature search was con-
ducted using Ovid Medline, Embase, and Cochrane Central
Register of controlled trials. No pharmacokinetic or dose-
finding studies of alemtuzumab have been performed in
kidney transplantation. Although such studies were con-
ducted in patients with CLL and MS, these findings cannot
be directly extrapolated to transplant recipients, because
CLL patients have a much higher load of CD52-positive
cells and, therefore, target-mediated clearance will differ
between these two indications. Alemtuzumab used as
induction therapy in kidney transplantation results in a
lower incidence of acute rejection compared to basiliximab
therapy and comparable results as compared with rabbit
anti-thymocyte globulin (rATG). Alemtuzumab used as
anti-rejection therapy results in a comparable graft survival
rate compared with rATG, although infusion-related side
effects appear to be less. There is a need for pharmacoki-
netic and dose-finding studies of alemtuzumab in kidney
transplant recipients to establish the optimal balance
between efficacy and toxicity. Furthermore, randomized
controlled trials with sufficient follow-up are necessary to
provide further evidence for the treatment of severe kidney
transplant rejection.
Key Points
Alemtuzumab, a monoclonal antibody against CD52,
is registered for the treatment of multiple sclerosis,
but is used off-label in patients with chronic
lymphocytic leukemia and as induction and anti-
rejection therapy after kidney transplantation.
Alemtuzumab causes a rapid and profound depletion
of T and B lymphocytes, as well as various cells of
the innate immune system. Reconstitution of cells
from the innate immune system is faster (within
6 months) than that of T and B lymphocytes, which
may take more than 1 year.
No pharmacokinetic studies of alemtuzumab exist
for kidney transplant recipients. The results of the
pharmacokinetic studies performed in patients with
chronic lymphocytic leukemia could not be
extrapolated directly to the kidney transplant
population because patients with chronic
lymphocytic leukemia have a much higher load of
CD52-positive (tumor) cells.
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1 Introduction
Alemtuzumab (Campath-1H) is a humanized, rat mono-
clonal IgG1 antibody with a molecular weight of approxi-
mately 150 kDa, directed against CD52. The depletion of
donor T lymphocytes from stem cell transplants to elimi-
nate graft-vs.-host disease was developed in the laboratory
of Herman Waldmann and Geoff Hale at the University of
Cambridge, UK [1]. The first anti-CD52 antibody devel-
oped was of the IgM class (Campath-1M), which was very
effective in eliminating T lymphocytes in vitro. In vivo,
there was a depletion of blood lymphocytes in stem cell
transplant recipients, but there was no depletion of lym-
phocytes in the bone marrow and no effect on solid lym-
phoma masses or splenomegaly [1, 2]. This fueled further
research and led to the development of a new IgG1 anti-
body (Campath-1G), which was found to result in long-
lasting depletion of lymphocytes from both blood and bone
marrow. A few years later, this antibody was humanized
(Campath-1H) to reduce the anti-globulin responses
(Fig. 1) [2–4].
In 2001, the US Food and Drug Administration and the
European Medicines Agency approved alemtuzumab for
the treatment of chronic lymphocytic leukemia (CLL)
under accelerated approval regulations [5]. Later, alem-
tuzumab was also approved by the Food and Drug
Administration (2014) and the European Medicines
Agency (2013) for the treatment of remitting-relapsing
multiple sclerosis (RRMS) and is currently marketed for
this indication under the name Lemtrada (Sanofi-Gen-
zyme, Cambridge, Massachusetts, United States) [6].
Following the market approval of Lemtrada, the approval
for the treatment of CLL was withdrawn (Fig. 1). How-
ever, alemtuzumab remains available for patients with CLL
via the worldwide Campath Distribution Program [7]. In
addition, alemtuzumab has also been used off-label for a
variety of other diseases and conditions, including the
prevention and treatment of acute rejection after solid
organ transplantation (SOT).
In recent years, there has been a renewed interest in the
use of alemtuzumab in SOT. In this review, we discuss the
pharmacokinetics and pharmacodynamics of alemtuzumab,
its use as induction and anti-rejection therapy in kidney
transplantation, and strategies to improve the outcomes of
alemtuzumab therapy.
2 Methods of Literature Search
A systematic literature search was performed (8 February,
2017) of Ovid MEDLINE, EMBASE, and the Cochrane
Central Register of controlled trials. The search terms
included ‘alemtuzumab’, ‘campath’, ‘pharmacokinetics’,
‘pharmacodynamics’, ‘induction therapy’, ‘rejection ther-
apy, and ‘adverse effects’ (see Electronic Supplementary
Material). The search revealed 1668 articles. After exclusion
of irrelevant articles (after reading the title and abstract), 730
articles remained, of which the relevant articles were inclu-
ded in this review. Examination of the reference list of the
included studies identified further studies. There were no
restrictions with regard to publication date. Only papers
published in English were included.
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Fig. 1 Timeline of alemtuzumab. In the 1980s, alemtuzumab was
called Campath and mainly used in hematology patients. Around
20 years later, alemtuzumab was approved for the treatment of
chronic lymphocytic leukemia (CLL) and for the first time in kidney
transplantation. A decade later, the registration of alemtuzumab for
CLL was withdrawn and alemtuzumab was approved as Lemtrada
for the treatment of multiple sclerosis (MS). In 2014, a large
randomized controlled trial compared alemtuzumab induction therapy
with basiliximab induction therapy. EMA European Medicines
Agency, FDA US Food and Drug Administration
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3 Pharmacodynamics of Alemtuzumab
CD52 is a 21–28 kDa cell surface glycoprotein attached to
the cell membrane by a glycosylphosphatidyl-inositol
anchor of 12 amino acids. CD52 is one of the most abun-
dant membrane glycoproteins on T and B lymphocytes and
is also expressed on natural killer (NK) cells, monocytes,
macrophages, dendritic cells, and eosinophilic granulocytes
and to a lesser extent on neutrophilic granulocytes [1, 8].
CD52 is not expressed on erythrocytes, platelets, and
hematopoietic progenitor cells [9]. The exact function of
CD52 is unknown but it is suggested that the molecule may
be involved in T lymphocyte co-stimulation, the induction
of regulatory T lymphocytes, and T lymphocyte migration
and adhesion [10, 11].
Administration of alemtuzumab causes a profound
depletion of T and B lymphocytes, NK cells, dendritic
cells, granulocytes, and monocytes by three mechanisms:
complement-dependent cytotoxicity (through C1q acti-
vation and subsequent generation of the membrane
attack complex), antibody-dependent cellular cytotoxic-
ity (after the activation of NK cells and macrophages
through their IgG fragment C receptor), and induction of
apoptosis (Fig. 2) [12, 13]. Depletion of peripheral
lymphocytes occurs within 1 h after alemtuzumab
administration. Lymphocyte depletion from secondary
lymphoid tissues occurs over 3–5 days [14]. Alem-
tuzumab administration significantly depletes peripheral
monocytes and NK cells [15].
Alemtuzumab has a long-lasting depletional effect. In
kidney transplant recipients receiving alemtuzumab as
induction therapy (40-mg total dose), B lymphocytes
recovered after 12 months. In contrast, T lymphocyte
numbers recovered to approximately 50% of baseline
36 months after alemtuzumab administration. CD8? T
lymphocytes repopulated more rapidly than CD4? T lym-
phocytes [16]. Cells of the innate immune system recon-
stitute faster than cells of the adaptive immune system.
After 1 month, more than half of the peripheral lympho-
cytes consists of NK cells and the number of NK cells
returns to 60–80% of baseline by 6 months [17]. Mono-
cytes are only mildly depleted and recover after 3 months
[16]. Dendritic cells recover to baseline levels 6 months
after alemtuzumab treatment [18].
Immunological reconstitution of T lymphocytes, either
partial or complete, appears to occur predominantly trough
homeostatic proliferation of residual CD4?CD25?Forkhead
box P3? (FoxP3?) regulatory lymphocytes, as well as
memory T lymphocytes and not by thymopoiesis [19].
Normally, levels of FoxP3? regulatory T lymphocytes in
kidney transplant recipientsmake up 3–4%of the total CD4?
population. After alemtuzumab treatment, a relative increase
of FoxP3? regulatory T lymphocytes is seen (up to 12%),
which persists for 2 years [20]. During immunological
reconstitution, skewing of the immune system to amore anti-
inflammatory pattern is observed: an increase in the per-
centage of the anti-inflammatory cytokines interleukin (IL)-
10 and transforming growth factor-b1 (produced by CD4?
and CD8? cells), an increased percentage of IL-4-producing
T-helper 2 cells, and decreased levels of proinflammatory
cytokines IL-17 and interferon (IFN)-c [21].
Anderson et al. described the reconstitution of T lympho-
cytes 12 years after treatment with alemtuzumab because of
rheumatoid arthritis [22]. Twenty patients treated with alem-
tuzumab were compared with 13 age-matched patients with
rheumatoid arthritis. Total CD4? lymphocyte counts were
lower in the alemtuzumab group compared with the controls
(median 0.55 9 109/L vs. 0.85 9 109/L; p = 0.0014). The
naı¨ve and central memory CD4? lymphocytes were signifi-
cantly reduced in the alemtuzumab-treated patients
[0.09 9 109/Lvs. 0.21 9 109/L (p = 0.0007) and0.1 9 109/
L vs. 0.36 9 109/L (p\ 0.0001), respectively]. However,
effectormemoryCD4? lymphocyte countswere not different.
Total CD8? lymphocytes were similar in both groups, but the
naı¨ve and central memory CD8? lymphocytes were signifi-
cantly lower in the alemtuzumab-treated patients
[0.05 9 109/L vs. 0.07 9 109/L (p = 0.0061) and
0.02 9 109/L vs. 0.04 9 109/L (p = 0.0342)] [22].
B lymphocyte reconstitution in patients treated with
alemtuzumab coincides with a high level of the cytokine
B lymphocyte activating factor (BAFF, also known asTALL-
1, BLyS, THANK, and zTNF4), which persists for over
12 months [23, 24]. From the second month after alem-
tuzumab administration, B lymphocytes start to repopulate.
First, the transitional B lymphocytes dominate, followed by
Bm2’ (mature naı¨ve) B lymphocytes [25]. Differentiation to
memory B lymphocytes is slow and reaches 25% of baseline
after 12 months [23, 24]. After alemtuzumab induction ther-
apy, there is an increased risk of formation of de novo donor-
specific anti-HLA antibodies (DSA) compared with basilix-
imab or anti-thymocyte globulin (ATG), which can lead to
chronic humoral immune responses against graft alloantigens
and subsequent graft failure [25, 26]. The authors hypothe-
sized that the spared alemtuzumab-resistant memory cells in
the presence of alloantigens can rapidly convert to plas-
mablasts and secrete donor-specific antibodies [25].
4 Pharmacokinetics of Alemtuzumab
4.1 Administration
Alemtuzumab is available as a solution for intravenous or
subcutaneous administration. A vial contains 30 mg in
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1 mL, or in the case of Lemtrada 12 mg in 10 mL. The
recommended dose depends on the indication for alem-
tuzumab. In RRMS, the initial treatment is 12 mg/day
intravenously for 5 consecutive days (cumulative dose of
60 mg) followed at 12 months by a second treatment
course with 12 mg/day for 3 consecutive days (cumulative
dose of 36 mg) [27]. For the indication CLL, it is advised
to start with a maximum dose of 3 mg, intravenously, a
second dose which is increased to 10 mg, which is fol-
lowed by a third dose of 30 mg. Thereafter, the recom-
mended alemtuzumab dose is 30 mg/day administered
three times weekly for a maximum of 12 weeks (maximum
cumulative dose 1080 mg) [28]. Dose recommendations
have also been made for the reduced-intensity hematopoi-
etic stem cell transplantation setting for non-malignant
hematologic disease [29]. A typical dosing scheme of
alemtuzumab in SOT is 1 or 2 gifts of 30 mg intravenously
or subcutaneously [30–32]. This dose is empirical and has
been deducted from the maximum dose used in hematol-
ogy. No formal dose-finding studies have been performed
in SOT recipients. It is recommended that patients are pre-
medicated with glucocorticoids, acetaminophen, and anti-
histamines immediately prior to the administration of
alemtuzumab to diminish infusion-related reactions
[33, 34].
4.2 Absorption
No pharmacokinetic studies of alemtuzumab have been
performed in SOT recipients, whereas in patients with CLL
and MS only a few such studies have been conducted. By
definition, the bioavailability of alemtuzumab is 100%
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Fig. 2 Mechanism of action of alemtuzumab. Alemtuzumab binds to
CD52 on target cells [T and B lymphocytes, natural killer (NK) cells,
monocytes, granulocytes, and dendritic cells] and via three pathways
depletion of the target cells occur. The antibody-dependent cellular
cytotoxicity involves the IgG fragment C receptor (FccR) on NK
cells, macrophages, and granulocytes. The FccR recognizes the Fc
region of alemtuzumab and binds to it. The NK cell, macrophage, or
granulocyte releases perforins and granzyme B, which causes lysis
and apoptosis of the target cell. In complement-dependent cytotox-
icity, the C1 complex (consisting of C1q, C1r, and C1s) binds to
alemtuzumab and this initiates the complement activation cascade and
subsequently the formation of the membrane attack complex (MAC).
Finally, binding of alemtuzumab to CD52 induces apoptosis directly.
IFN interferon
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after intravenous administration. In one study, the maxi-
mum plasma concentration (Cmax) of intravenously
administered alemtuzumab was evaluated in 216 patients
with RRMS [34]. Administration of 12 mg per day for 5
consecutive days resulted in a mean Cmax of 3014 ng/mL
directly after the last administration on day 5. In patients
with CLL, Cmax of 2800–26,400 ng/mL (mean 10,700 ng/
mL) were measured after intravenous administration of
30 mg three times a week for 8 weeks [35].
Alemtuzumab can also be administered subcutaneously.
Subcutaneous administration is more convenient and cau-
ses fewer infusion-related reactions as compared with
intravenous administration [36, 37]. The bioavailability of
subcutaneously administered alemtuzumab was studied in
cynomolgus monkeys. Doses of 1, 2, and 3 mg/kg were
slowly absorbed from the site of injection and the time to
reach Cmax was around 48 h. The bioavailability after
subcutaneous administration was approximately 47% [28].
In humans, Hale et al. [35] compared blood concentrations
from patients with CLL treated either intravenously or
subcutaneously (30 mg three times weekly). The highest
measured pre-dose concentrations were similar between
the two routes of administration (mean 5400 ng/mL). To
reach a pre-dose concentration of 1000 ng/mL (an arbitrary
threshold known to be potentially lympholytic), a higher
cumulative dose was required when the drug was given
subcutaneously as compared with intravenous administra-
tion (1106 and 146 mg, respectively).
Induction therapy with alemtuzumab in simultaneous
pancreas-kidney transplant (SPKT) recipients showed no
clinical difference between subcutaneous or intravenous
therapy. Total lymphocyte and CD3? lymphocyte deple-
tions were not significantly different and the incidence of
acute rejection episodes, as well as patient survival, were
comparable in the two groups [31].
4.3 Distribution
Because of its size, alemtuzumab is not likely to cross cell
membranes and is therefore expected to distribute between
the plasma and interstitial space. In patients with MS, the
volume of distribution was reported to be 14.1 L [34]. To
measure the volume of distribution in patients with CLL,
Mould et al. [38] pooled the data of 67 patients from four
studies. This resulted in a steady-state volume of distri-
bution of 11.3 L.
In addition to being expressed on the cell surface, CD52
also exists in a soluble form. Soluble CD52 can bind
alemtuzumab, form immune complexes, and thereby
reduce the amount of free and bioactive drug. Soluble
CD52 levels are likely to be lower in patients with MS and
recipients undergoing SOT compared with patients with
CLL [39]. Higher plasma levels of soluble CD52 may
require higher doses of alemtuzumab for sufficient efficacy
[40]. There are no data on the binding of alemtuzumab to
other plasma proteins.
4.4 Metabolism and Elimination
The half-life of alemtuzumab depends on the concentration
of its target. In the case of a high concentration of CD52,
such as in patients with CLL with a large tumor burden, the
half-life of alemtuzumab is short because binding of
alemtuzumab to CD52 leads to cytotoxicity of malignant
cells and rapid receptor-mediated clearance from the blood.
When CD52 levels decrease (following successful treat-
ment), the half-life of alemtuzumab increases. Therefore,
patients with CLL will require a higher cumulative dose
than patients treated for another indication. The half-life of
alemtuzumab in patients with CLL is 6.1 days and in stem
cell transplant recipients it is 8–21 days [35, 41, 42]. The
half-life of alemtuzumab in patients with RRMS (12 mg on
5 consecutive days) was approximately 4–5 days and low
or undetectable serum concentrations were measured
within 30 days after completion of the course [34].
The mechanism of clearance of alemtuzumab from the
circulation and interstitial space is not well understood. In a
study of patients with CLL, alemtuzumab showed time-
and concentration-dependent pharmacokinetics with (non-
linear) clearance with large inter-patient variability [38].
This is probably explained by a difference in tumor burden.
It is not known whether individual variations in factors
such as hepatic function or macrophage activity affect the
elimination rate of alemtuzumab [43]. No studies of the
pharmacokinetics of alemtuzumab have been performed in
patients with renal insufficiency or hepatic impairment.
It is also unknown if alemtuzumab binds to the neonatal
Fc-receptor like some other monoclonal antibodies. The
Fc-receptor is expressed on endothelial cells and influences
the half-life of IgG1 by internalization of immunoglobulins
and protection from lysosomal degradation [44].
The expected metabolic pathway of alemtuzumab is
degradation to small peptides and individual amino acids
by widely distributed proteolytic enzymes. Classical bio-
transformation studies have not been conducted but are
unlikely to be relevant for alemtuzumab clearance [34].
There is no known antidote available in the case of an
accidental overdose and treatment consists of supportive
measures [34]. The effect of hemodialysis on the plasma
concentration of alemtuzumab is unknown. However, it is
unlikely that alemtuzumab is removed with hemodialysis
because of its size (150 kDa). Likewise, no studies inves-
tigated if alemtuzumab is removed by plasmapheresis. For
the monoclonal antibody rituximab, it is known that
plasmapheresis removes an important proportion of the
drug if performed within the first 72 h after administration
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[45]. Like rituximab, alemtuzumab has a small volume of
distribution and it is therefore likely that plasmapheresis
can reduce the plasma concentration of alemtuzumab.
However, the depletional effect on peripheral lymphocytes
is seen in the first hour after alemtuzumab administration.
4.5 Immunogenicity
Alemtuzumab is a recombinant humanized protein with a
variable framework with constant regions from a human
IgG1 immunoglobulin and six complementarity-determin-
ing regions from a rat IgG2a antibody. The humanization of
alemtuzumab has reduced the risk of antiglobulin respon-
ses [46]. However, anti-drug antibodies are still observed
after administration of alemtuzumab [35, 46].
In patients with CLL, no patient developed anti-alem-
tuzumab antibodies in the group treated with intravenous
alemtuzumab (n = 30), whereas two patients in the group
given subcutaneous alemtuzumab developed such anti-
bodies (n = 32). The antibodies likely inactivated alem-
tuzumab because these two patients did not show a
significant reduction in lymphocyte count following
alemtuzumab administration [35].
The phase III studies CARE MSI (Comparison of
alemtuzumab and Rebif efficacy) and CARE MSII (trials
performed in patients with MS) showed a much higher
percentage of anti-alemtuzumab antibodies. These anti-
bodies were detectable in 29% of patients just before the
second course of alemtuzumab (12 months after the last
alemtuzumab gift) and in 81–86% of patients 1 month after
the second course. Although the presence of anti-alem-
tuzumab antibodies was associated with a lower alem-
tuzumab concentration after the second course, the clinical
outcome, lymphocyte depletion, and repopulation were not
influenced [47, 48]. Rebello et al. described 12 patients
treated with alemtuzumab because of kidney transplant
rejection. No anti-alemtuzumab antibodies were detected
[46].
Many factors possibly influence the immunogenicity of
alemtuzumab including the dose and length of treatment,
the route of administration, prior exposure to chemother-
apy, and the concomitant use of other immunosuppressive
drugs [46, 49]. Additionally, the incidence of anti-alem-
tuzumab antibodies is dependent on the sensitivity and
specificity of the assay that is used.
5 Therapeutic Drug Monitoring
Pharmacokinetic monitoring is performed by three
assays to measure alemtuzumab concentrations: an
enzyme-linked immunosorbent assay, an indirect
immunofluorescence method with flow cytometry
detection, and liquid chromatography-tandem mass
spectrometry [50–52].
For enzyme-linked immunosorbent assay, serum sam-
ples are added to microtiter plates that contain rabbit anti-
rat IgG antibodies that recognize the remaining rat
sequence in the alemtuzumab molecule [50]. After incu-
bation, the plates are washed and incubated with peroxi-
dase-conjugated, affinity purified rabbit anti-human Fc.
After washing, the substrate (3,30-5,50-tetramethylben-
zidine; Dako, Carpinteria, CA, USA) is added. The reac-
tion is stopped with hydrochloride and the signal is
measured with a spectrophotometer. No significant differ-
ence was seen between serum or plasma. The lower limit of
detection of the assay is 0.05 lg/mL [50].
Alemtuzumab can also be measured by means of flow
cytometry. For this technique, a HUT-78 cell line is used.
This CD8? T-cell line is derived from a patient with Se´zary
syndrome and expresses high levels of CD52 [53]. The cell
line is incubated with the serum of the patient treated with
alemtuzumab. After washing, fluorescein isothiocyanate-
labeled polyclonal anti-human Ig Fc antibodies are added
and fluorescence is measured by flow cytometry. The lower
limit of detection is 0.15 lg/L and the lower limit of
quantification is 0.25 lg/L [51]. Recently, Marsh et al.
used flow cytometry with normal donor, peripheral blood
mononuclear cells instead of the HUT-78 cell line to
measure alemtuzumab concentrations [54]. The lower limit
of detection was 0.02 lg/mL, which is lower than that of
the HUT-78 cell line-based assay [54].
Mass spectrometry has been described as a method to
measure alemtuzumab [52]. It is currently not frequently
used for the measurement of alemtuzumab. However, liq-
uid chromatography-tandem mass spectrometry might
become an important method to measure the blood con-
centrations of monoclonal antibodies in the future [55].
Pharmacodynamic monitoring is mainly performed by flow
cytometry to quantify the numbers of circulating T and B
lymphocytes and NK cells.
From the above, it is clear that measuring the serum or
plasma concentration of alemtuzumab is possible. How-
ever, these assays are not widely available, technically
demanding, and difficult to standardize. In SOT, no formal
dose-finding studies exist and at present there are no tests
that support specific alemtuzumab target concentrations,
with an optimal balance between efficacy and toxicity.
Such studies have been performed in patients undergoing
hematopoietic stem cell transplantation, and pharmacoki-
netic-pharmacodynamic model target concentrations for
this specific population have been proposed (personal
communication, R. Admiraal, Leiden University Medical
Center, Leiden, The Netherlands).
196 M. van der Zwan et al.
6 Clinical Use of Alemtuzumab in Kidney
Transplantation
Alemtuzumab is not registered for SOT indications.
However, the drug has been used off-label for both the
prevention and treatment of acute allograft rejection in
kidney, pancreas, intestinal, and lung transplantation.
6.1 Alemtuzumab as Induction Therapy
6.1.1 Kidney Transplantation
In many transplant centers, induction therapy is used to
reduce early rejection rates. Two types of induction therapy
are recognized: T lymphocyte-depleting antibody therapy
and antibody therapy directed against IL-2 receptor.
Basiliximab is a non-depleting monoclonal antibody
directed against the IL-2 receptor, whereas ATG and
alemtuzumab are depleting antibodies. Alemtuzumab was
first used as induction therapy in 1998 in a case series of 13
kidney transplant recipients. The patients received induc-
tion therapy with alemtuzumab (two doses of alemtuzumab
20 mg intravenously on day 0 and 1) followed by low-dose
ciclosporin as maintenance therapy. In the 6- to 11-month
follow-up, only one patient experienced acute rejection
[56].
Following this initial experience, the efficacy of alem-
tuzumab to prevent acute rejection following kidney
transplantation was compared with IL-2 receptor antibod-
ies in randomized controlled trials (RCTs). A systematic
review of five of these RCTs described a reduced risk of
acute rejection using alemtuzumab as compared with an
IL-2 receptor antagonist at 12 months after kidney trans-
plantation [659 patients; relative risk = 0.54; 95% confi-
dence interval (CI) 0.37–0.79; p\ 0.01] [57]. No
significant difference was seen in graft loss, delayed graft
function, or patient survival.
Recently, the results of the first phase of the ‘Campath,
calcineurin inhibitor reduction and chronic allograft
nephropathy’ (3C) study were published. The hypothesis of
this RCT was that a more potent induction therapy at the
time of transplantation allows for minimization of tacroli-
mus exposure without an increased risk of acute rejection.
An immunosuppressive regimen with reduced exposure to
the nephrotoxic tacrolimus could potentially lead to better
renal function and longer graft survival. In the 3C study,
induction therapy with alemtuzumab (30 mg on days 0 and
1, subcutaneously or intravenously) was compared with
basiliximab (20 mg intravenously on days 0 and 4). A total
of 852 patients were included (n = 426 in the alem-
tuzumab and n = 426 in the control arm). Patients in the
alemtuzumab arm were co-treated with low-dose
tacrolimus (aiming for pre-dose concentrations of 5–7 ng/
mL) and mycophenolate sodium (360 mg twice daily)
without glucocorticoids. In the control arm, basiliximab-
treated patients were co-treated with a standard-dose
tacrolimus (target pre-dose concentrations 5–12 ng/mL),
mycophenolate sodium (540–720 mg twice daily), and
glucocorticoids (15–20 mg prednisone, withdrawn in
accordance with local practice).
The primary endpoint of the 3C study was the incidence
of biopsy-proven acute rejection (BPAR) at month 6 after
transplantation. Induction therapy with alemtuzumab in
combination with low-dose tacrolimus and mycophenolate
sodium without glucocorticoids significantly reduced the
incidence of BPAR: 26 (6.1%) vs. 65 (15.3%; p\ 0.0001,
hazard ratio 0.37; 95% CI 0.23–0.58), for the alemtuzumab
and control arms, respectively. No significant difference
was seen in the occurrence of biopsy-proven antibody-
mediated rejection (ABMR): 8 (1.9%) vs. 5 (1.2%)
(p = 0.41, hazard ratio 1.59; 95% CI 0.52–4.86). There
was no difference 6 months after randomization between
the two groups in terms of graft function (mean eGFR
50.1 mL/min per 1.73 m2 in the alemtuzumab-treated
patients vs. 49.8 mL/min per 1.73 m2 in the basiliximab-
treated group), the incidence of graft failure, mortality, or
serious infection [58]. Limitations of the 3C study were the
short follow-up duration of 6 months and no blinding of the
induction therapies. In addition, the difference in tacroli-
mus exposure was limited: The average pre-dose concen-
tration of tacrolimus in the alemtuzumab-treated patients
was 6.9 ng/mL and in basiliximab-treated patients was
8.3 ng/mL [59].
Hanaway et al. compared alemtuzumab induction ther-
apy (a single shot of 30 mg, intravenously) with basilix-
imab induction therapy (in patients with low risk of acute
rejection) or with rabbit ATG (rATG) induction therapy in
high-risk patients. A high risk of acute rejection was
defined as a panel-reactive antibody (historical or current)
above 20%, repeat transplantation, or black ethnicity.
There were 139 high-risk patients; 70 received alem-
tuzumab and 69 received rATG. In the low-risk group, 335
patients were included; 164 received alemtuzumab and 171
patients received basiliximab. Basiliximab was given on
day 0 and days 3, 4, or 5 (20 mg per gift). The total dose of
rATG was 6 mg/kg (divided over four gifts). All patients
received tacrolimus (target pre-dose concentration of
7–14 ng/mL in the first 3 months after transplantation, and
4–12 ng/mL after month 3), mycophenolate mofetil
(1000 mg twice daily), and glucocorticoids (withdrawn on
post-operative day 5). The rate of BPAR at 12 months in
the alemtuzumab group was lower than in the basiliximab-
treated patients (3 vs. 20%, p\ 0.0001). No significant
difference in BPAR after month 12 was observed between
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alemtuzumab and rATG in the high-risk group (10 vs.
13%, p = 0.53) [60].
A systematic review with a meta-analysis compared
induction therapy with alemtuzumab to rATG. A total of
446 patients was included and a comparable incidence of
BPAR (relative risk = 0.79; 95% CI 0.52–1.21; p = 0.28)
was seen. There was also no significant difference in graft
loss and overall survival [57]. A recent Cochrane system-
atic review also showed comparable rates of BPAR
between alemtuzumab and rATG in a total of six studies
(446 patients; RR 0.68; 95% CI 0.44–1.05; p = 0.66).
However, rates of BPAR after alemtuzumab induction
were lower in four studies with early glucocorticoid with-
drawal (360 patients; RR 0.57; 95% CI 0.35–0.93;
p = 0.025). Rabbit ATG plus glucocorticoid continuation
vs. alemtuzumab plus early glucocorticoid withdrawal
showed no difference between the two groups (two studies;
86 patients, relative risk (sometimes RR is used and other
times relative risk) 1.27, 95% CI 0.5–3.19; p = 0.57) [61].
Although no higher rejection rate was seen after alem-
tuzumab induction therapy in the studies described above,
higher rates of acute ABMR have been described in a few
studies [62–64]. LaMattina et al. [64] compared in a ret-
rospective study induction therapy with alemtuzumab
(n = 632), basiliximab (n = 690), or rATG (n = 125).
Alemtuzumab was given one or two times (30 mg), basil-
iximab was administered on postoperative day 0 and 4
(20 mg), and the total dose of rATG was 6–8 mg/kg.
Maintenance immunosuppression consisted of tacrolimus
or ciclosporin in combination with mycophenolate mofetil
and glucocorticoids (tapered to 5–10 mg/day after the first
post-operative month). No significant difference was seen
in overall frequency of BPAR; however, ABMR was sig-
nificantly increased in the group of patients treated with
alemtuzumab induction therapy compared with the group
treated with rATG or basiliximab induction therapy. The
1-, 3-, and 5-year cumulative incidence of alemtuzumab-
treated patients was 18.8, 23.8, and 26.5% respectively, vs.
11.3, 15.2, and 17.6% for the group receiving rATG or
basiliximab (p\ 0.0001). The higher incidence of ABMR
could have been caused by a higher incidence of DSA after
alemtuzumab treatment; however, this study did not test for
the presence of DSA.
6.1.2 Simultaneous Pancreas-Kidney Transplantation
Adding a pancreas allograft to a kidney transplant seems to
increase the risk of acute rejection. Over 90% of SPKT
recipients receive antibody induction, with nearly 80%
receiving a T lymphocyte-depleting antibody [65].
In a single-center RCT, 28 SPKT recipients treated with
alemtuzumab induction were compared with 18 SPKT
patients treated with rATG. Alemtuzumab induction
consisted of a single dose of 30 mg intravenously or rATG
(cumulative dose 5–6 mg/kg). All patients received main-
tenance immunosuppression consisting of tacrolimus,
mycophenolate mofetil, and glucocorticoids (with com-
plete withdrawal on post-operative day 5). Patients iden-
tified as being of high immunological risk remained on
maintenance glucocorticoids. In this underpowered study,
no significant difference was seen in the frequency of
rejection after 1 year (18 and 39%, respectively, for
alemtuzumab and rATG; p = 0.17)) and 5 years (21 and
44%; p = 0.12). Total patient survival after 5 years was
not significantly different (82 vs. 89% for alemtuzumab
and rATG, respectively). Furthermore, after 5 years, no
significant difference was seen in kidney graft survival
(78.6 vs. 66.7%) and pancreas graft survival (64.3 vs.
55.5%) [66].
Alemtuzumab induction therapy was compared with
basiliximab in a retrospective cohort study of 136 SPKT
recipients. All patients received maintenance immunosup-
pression with tacrolimus, mycophenolate mofetil, and
glucocorticoids. Basiliximab was given to 39 patients and
alemtuzumab (30 mg, on days 0 and 1) was given to 97
patients. Acute cellular rejection of the kidney was sig-
nificantly less frequent in the alemtuzumab-treated patients
(3.1 vs. 15.4%, p = 0.017). The occurrence of ABMR was
not different between the two groups (18 vs. 14.4%,
p = 0.6, for alemtuzumab and basiliximab, respectively).
After 3 years, no significant difference was seen in patient
survival or allograft survival of the kidney (86.2% for
alemtuzumab and 91.8% for basiliximab) or pancreas
(88.6% for alemtuzumab and 81.8% for basiliximab) [67].
Taken together, alemtuzumab is frequently used as an
induction agent in SOT. Compared with basiliximab
induction therapy, alemtuzumab results in a lower inci-
dence of acute rejection. However, when compared with
rATG no difference in the risk of acute rejection was
observed. Graft survival and patient survival are mostly
comparable between induction therapy with alemtuzumab
and basiliximab or rATG.
6.2 Alemtuzumab as Anti-Rejection Therapy
In most centers, the first-line treatment of BPAR after a
kidney transplant is pulse therapy with glucocorticoids. In
the case of glucocorticoid-resistant rejection or severe
(histological grade) rejection, depleting antibody therapy is
indicated [68]. The standard depleting antibody is rATG
[69]. However, treatment with ATG has limitations. First,
ATG must be administered via a high-flow intravenous
access (often a central venous catheter) or an arteriovenous
fistula to avoid thrombophlebitis. Second, administration of
ATG can cause cytokine release syndrome immediately
after infusion. Cytokine release syndrome is characterized
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by fever, hypotension, pulmonary edema, nausea, tachy-
cardia, rash, or chills. Furthermore, anti-rabbit antibodies
can form after rATG administration. In the case of subse-
quent exposure to rATG, this can lead to diminished
activity and adverse reactions such as serum sickness [70].
An alternative treatment would be necessary in these
patients.
Alemtuzumab has incidentally been used as a treatment
of BPAR after kidney transplantation [30, 32, 46, 71–73].
No RCTs investigating this application have been per-
formed. Clatworthy et al. [73] described the long-term
outcome of first-line treatment of BPAR with alem-
tuzumab. Of the 15 patients described in this retrospective
case series, 12 patients were diagnosed with an acute cel-
lular rejection, one with an ABMR, and two with a mixed-
type rejection. Alemtuzumab was administered intra-
venously and the first six patients were treated with 10 mg
per day for 7 days (cumulative dose of 70 mg). The
remaining nine patients received alemtuzumab in a dose of
6 mg/day for 4–10 days. The control group consisted of 25
patients with an acute rejection treated in the same period
with intravenous methylprednisolone (1000 mg/day for 3
consecutive days). Of the 25 biopsies, 22 showed acute
cellular rejection and three mixed-type rejections. Main-
tenance immunosuppressive therapy consisted of ciclos-
porin, azathioprine, and glucocorticoids. Baseline
characteristics were comparable in both groups. All rejec-
tion episodes were treated successfully, as shown by a fall
in serum creatinine within 3–10 days of treatment. Long-
term transplant survival and allograft function were similar
in both groups. There was no excess rate of cytomegalo-
virus infection, malignancy, autoimmunity, or post-trans-
plant lymphoproliferative disorder in the alemtuzumab-
treated patients. Serious infections during the first year
were noted in 47% of patients treated with alemtuzumab
and three patients died in the first year because of infection.
In conclusion, this study demonstrates that treatment of
acute rejection with alemtuzumab results in comparable
long-term outcomes as with methylprednisolone pulse
treatment; however, with an excess of infection-related
death in the first year after treatment [73].
Alemtuzumab has also been used as second-line treat-
ment in glucocorticoid-resistant or severe acute rejection.
Basu et al. described 40 patients with glucocorticoid-re-
sistant rejection (29 patients) or severe rejections (Banff 1B
or worse, 11 patients). No control group was included. The
patients were treated with alemtuzumab intravenously
(30 mg, one to four doses). All patients had previously
received induction therapy consisting of rATG or alem-
tuzumab followed by tacrolimus monotherapy as mainte-
nance immunosuppression. Graft survival after a mean
duration of 453 ± 163 days was 62.5%. In 14 patients,
infectious complications occurred. Two patients died: one
patient developed post-transplant lymphoproliferative dis-
order and the other patient died because of an intraab-
dominal abscess [72]. The authors concluded that the
outcome after treatment with alemtuzumab is comparable
to the outcome of other antibody preparations (indirect
comparisons with RCTs). However, infectious complica-
tions were frequent [72].
Another retrospective study compared alemtuzumab
with rATG for the treatment of glucocorticoid-resistant
rejection. Eleven patients were treated with 15–30 mg of
alemtuzumab (subcutaneously) for 1–2 consecutive days.
The reason for treating these patients with alemtuzumab
were as follows: fluid overload, positive test for anti-rabbit
IgG antibodies, treatment with ATG after previous trans-
plantation, and cardiac ischemia. Three patients had no
contra-indication for ATG. The control group consisted of
20 patients treated with rATG (2.5–4.0 mg/kg for
10–14 days). These historical controls consisted of patients
with a glucocorticoid-resistant rejection and were matched
for date after transplantation. The endpoint of this small
study was a composite endpoint named ‘treatment failure’
after 3 months, which was defined as graft loss, the need
for additional anti-rejection therapy, or the lack of
improvement of renal allograft function (drop of less than
25% of serum creatinine at 3 months after treatment with
alemtuzumab or rATG). The incidence of treatment failure
was comparable in both groups (alemtuzumab 27% vs.
rATG 40%, p = 0.89) [30].
Taken together, anti-rejection therapy with alem-
tuzumab results in a comparable graft survival compared
with rATG. However, head-to-head RCTs with a rATG
control and with longer follow-up are necessary to support
this conclusion.
6.3 Alemtuzumab in Pediatric Kidney
Transplantation
Reducing the toxicity of immunosuppressive drugs is of
paramount importance in pediatric kidney transplant
recipients. In particular, the minimization of glucocorti-
coids, which can cause, among others growth retardation,
post-transplant diabetes mellitus, and weight gain, is an
important goal in this population. Induction therapy with
alemtuzumab has been used incidentally to avoid gluco-
corticoids and reduce calcineurin inhibitor exposure but no
prospective, randomized controlled clinical trials compar-
ing different induction therapies have been performed in
children [74–83]. Several reasons may exist why limited
studies have been performed with alemtuzumab in chil-
dren. First, most children are unsensitized at the time of
transplantation because most patients did not have prior
kidney transplantations or pregnancies. Second, physicians
may be concerned for the development of primo-
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cytomegalovirus and Epstein–Barr virus (EBV) infections
and EBV-related post-transplant lymphoproliferative dis-
ease (PTLD) after alemtuzumab administration.
The first experience with alemtuzumab as induction
therapy in pediatric kidney transplant recipients was
described in 2005 [75]. Four patients ranging from
20 months to 16 years of age received alemtuzumab
intraoperatively (one dose of 30 mg in three patients and
two doses of 30 mg in one patient). Three patients also
received a calcineurin inhibitor, mycophenolate mofetil
with or without corticosteroids as maintenance immuno-
suppressive therapy. In the fourth patient, calcineurin
inhibitor therapy was withheld because of concerns for the
recurrence of Factor H, deficiency-associated hemolytic
uremic syndrome. In the short follow-up period of
5–12 months, three children experienced acute rejection
(of which two were C4d positive, suggesting an antibody-
mediated rejection) without graft loss. No serious infec-
tions or PTLD occurred [75]. White blood cell counts were
measured by flow cytometry in one patient and demon-
strated that CD3?, CD4?, CD8?, and CD20? lymphocyte
counts had recovered to 50% of baseline 1 year after
administration. Monocytes recovered to baseline level by
month 3 [75].
After this initial and disappointing experience, better
results were obtained in a larger case series of 42 pediatric
kidney transplant patients (mean age 9.0 years) treated
with alemtuzumab induction therapy (in a dose of
0.4–0.5 mg/kg intravenously) followed by tacrolimus
monotherapy [76]. The mean follow-up was 24.1 months.
The aim of tacrolimus dosing was a pre-dose concentration
of 8–12 ng/mL in the first 6 months. In the case of no
rejection and in the absence of the development of de novo
DSA and graft dysfunction, the tacrolimus dose was low-
ered to every other day. This strategy was successful in 12
patients. Only two patients experienced an episode of an
acute cellular rejection and no cases of acute antibody-
mediated rejection were observed. The 4-year graft sur-
vival rate was 85.4%. No cases of cytomegalovirus infec-
tion were seen and two patients were diagnosed with BK
viremia. No PTLD or serious infections occurred. Two
children died: one of an unknown cause and one because of
a disconnected tracheostomy at home [76].
A larger case series of 101 pediatric kidney transplant
patients (mean age 10.7 years) described a different out-
come regarding the incidence of rejection and infection
[77]. The patients were treated with two 30-mg doses of
alemtuzumab: the first dose 12–29 days before transplan-
tation and the second dose on the day of transplantation.
The mean follow-up was 3.8 years. Maintenance therapy
consisted of a calcineurin inhibitor (tacrolimus or ciclos-
porin) in combination with mycophenolate mofetil. Glu-
cocorticoids were discontinued around day 5 if the graft
function was acceptable and target calcineurin blood con-
centrations were reached. The incidence of acute rejection
(including subclinical rejections) was 37%. In four
patients, rejection led to graft loss. Overall graft survival
was 89.1% after 3 years. Cytomegalovirus and BK viremia
occurred mostly during the first 3 months (30 and 25%,
respectively). Twenty percent of patients experienced EBV
viremia by year 2. No patients developed PTLD. Eight
patients died (range 26–1457 days) of which five were
because of an infection [77].
In a phase II multicenter prospective analysis, 35 pedi-
atric kidney transplant patients were treated with one gift of
alemtuzumab (0.3 mg/kg, maximum 20 mg) as induction
therapy [84]. The primary aim of this study was to char-
acterize the reconstitution of lymphocyte subsets in pedi-
atric renal transplant recipients after alemtuzumab
induction therapy followed by calcineurin inhibitor with-
drawal. The patients were unsensitized and were first-time
recipients with living donors. Maintenance immunosup-
pressive therapy consisted of tacrolimus and mycopheno-
late mofetil. Tacrolimus was switched to sirolimus after
2–3 months. In the follow-up period of 2 years, six patients
developed acute rejection. Two patients experienced graft
loss: one to focal and segmental glomerulosclerosis and
one to non-adherence of medication. Fourteen children
experienced infectious episodes. The reconstitution of the
lymphocytes in these patients mimicked the pattern seen in
adults. CD8? T lymphocytes recovered faster than CD4?
lymphocytes: after 24 months, CD8? T lymphocytes
recovered to 60% of baseline and CD4? lymphocytes to
25% of baseline (p = 0.014). No significant difference was
seen in the recovery of CD4? naı¨ve and memory lym-
phocyte subsets and CD8? naı¨ve and memory lympho-
cytes. In the CD4? memory lymphocyte population, the
effector memory lymphocytes recovered faster than the
central memory lymphocytes (44 vs. 24% after 24 months,
respectively; p = 0.027). No significant difference was
seen in the recovery of CD8? central memory and effector
memory lymphocytes. At baseline, 4% of CD4? lympho-
cytes were CD4?CD25?FoxP3? regulatory T lympho-
cytes. Three months after alemtuzumab, there was
relatively less depletion of regulatory CD4? lymphocytes
(around 10% of the CD4? cells had a regulatory T lym-
phocyte phenotype) and this effect persisted for 12 months
of alemtuzumab treatment [84].
Alemtuzumab has also been successfully used as part of
the induction therapy in highly sensitized, pediatric kidney
transplant patients in two small case series [85, 86]. To our
knowledge, only one paper has described the use of
alemtuzumab as anti-rejection therapy in pediatric kidney
transplant recipients [87]. Three patients were treated with
alemtuzumab (0.3 mg/kg, intravenously) because of five
episodes of a late (i.e., more than 3 months after
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transplantation) glucocorticoid-resistant acute rejection.
All patients were treated with ATG on two previous
occasions. The first 14-year-old patient experienced
recurrent rejection because of non-adherence. The first two
episodes [acute cellular rejection (ACR) Banff type 1B]
responded well to alemtuzumab. The third episode (ACR
Banff type 1A) did not respond and the patient experienced
graft loss soon thereafter. The second patient (14 years old)
received one gift of alemtuzumab because of an ACR
Banff type 1B. The serum creatinine concentration dropped
from 292 to 150 lmol/L 1 week after the administration of
alemtuzumab. Two months after the alemtuzumab treat-
ment, the patient experienced a borderline rejection with
good response to high-dose glucocorticoids. The serum
creatinine concentration stabilized around 175 lmol/L.
The absolute lymphocyte count recovered to baseline level
after 23 months. After 10 months, there was an asymp-
tomatic rise in serum EBV load with spontaneous resolu-
tion. The third patient (5 years old) experienced an ACR
Banff type 1B-2A. He was treated unsuccessfully with
methylprednisolone, ATG, rituximab, intravenous
immunoglobulins, and finally alemtuzumab, after which he
lost his graft. In the year after the anti-rejection treatment,
this patient experienced multiple serious infections proba-
bly related to the severe leukopenia, which required treat-
ment with granulocyte colony-stimulating factor [87]. In
conclusion, alemtuzumab reversed three of five rejection
episodes in pediatric patients with a late glucocorticoid-
and ATG-resistant rejection. However, it did not prevent
graft loss in two of the three patients.
In summary, alemtuzumab is sometimes used as
induction therapy and rarely as anti-rejection therapy in
pediatric renal transplant recipients. The results are vari-
able and different dosing schemes (some are weight
adjusted and some not) of alemtuzumab are used.
Prospective randomized controlled trials comparing dif-
ferent induction therapies (such as basiliximab, ATG, and
alemtuzumab) are needed to establish the efficacy and
long-term safety of alemtuzumab in pediatric renal trans-
plant recipients.
7 Complications of Alemtuzumab Administration
7.1 Infusion-Associated Reactions
Acute infusion-related reactions occur in 70–80% of
patients during treatment with alemtuzumab when given
intravenously. These reactions are caused by cytokine
release from lysed immune cells. These reactions are
mostly mild to moderate and include headache, rash, nau-
sea, hypotension, rigors, and pyrexia. Following subcuta-
neous administration, infusion-related reactions occur less
frequently, although local injection-site reactions do occur
[34, 37].
7.2 Infections
Alemtuzumab results in a prolonged depletion of T and B
lymphocytes (usually for over 12 months). This profound
immunosuppression predisposes patients to infections.
However, no depletion of the neutrophilic granulocytes
typically occurs and reconstitution of the cells of the innate
immune system is faster: monocytes typically recover after
3 months (although repopulation may occur in as little as
1 month) and NK cells return to 60–80% of baseline after
6 months).
Prophylaxis with an oral anti-herpes agent and prophy-
laxis against Pneumocystis jirovecii should be started
directly after administration of alemtuzumab and be con-
tinued for a minimum of 2 months after the last alem-
tuzumab gift or until the CD4? T lymphocyte count is
C200 cells/lL [33, 34]. In our center, we do not routinely
screen kidney transplant recipients for adenovirus or EBV,
whereas we do for BK virus.
Published data on the occurrence of opportunistic
infections after alemtuzumab treatment are limited. BK
virus infection is more common after alemtuzumab
induction in kidney transplantation compared with ATG
induction [32]. Cytomegalovirus and opportunistic and
non-opportunistic infections were not more common when
comparing alemtuzumab with ATG induction therapy [32].
In contrast to induction therapy with alemtuzumab, anti-
rejection therapy with alemtuzumab is associated with a
higher risk of opportunistic infections (4.5 vs. 21%
p\ 0.001). The higher incidence of opportunistic infec-
tions may be directly related to the alemtuzumab treatment,
but could also be owing to the fact that after rejection the
maintenance immunosuppressive therapy is also intensified
[88].
7.3 Malignancy
Long-term data linking alemtuzumab treatment with
malignancy are scarce and the risk of developing malig-
nancy is poorly defined. In a single-center retrospective
analysis among 1350 kidney transplant recipients, no
increased cancer incidence 4 years after induction therapy
with alemtuzumab (2.8%) compared with ATG (5.4%) or
no induction therapy (3.3%) was seen (across all groups;
p = 0.234). This study did not include non-melanoma skin
cancer [89].
In contrast, another study using US transplantation and
cancer registries data to explore the relationship between
induction therapy and cancer after transplantation came to
a different conclusion [90]. A total of 111,857 kidney
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transplant recipients were available for inclusion with a
median follow-up of 3.5 years. Of the total group, 3394
patients received alemtuzumab induction therapy. Alem-
tuzumab induction, compared with no induction therapy,
was associated with an increased risk of non-Hodgkin
lymphoma [n = 15, adjusted incidence rate ratio (aIRR),
1.79; 95% CI 1.02–3.14; p = 0.04] and all virus-related
tumors such as non-Hodgkin lymphoma, Hodgkin lym-
phoma, human papilloma virus-related cancers, Kaposi
sarcoma, and liver cancer (n = 19, aIRR 1.84; 95% CI
1.11–3.03; p = 0.02). Alemtuzumab induction was also
associated with increased colorectal cancer (n = 7, aIRR
2.46; 95% CI, 1.03–5.91; p = 0.04) and thyroid cancer
(n = 10, aIRR 3.37; 95% CI 1.55–7.33; p = 0.002).
Alemtuzumab induction was not associated with an
increased risk of lung or kidney cancer, or melanoma [90].
No direct comparison between alemtuzumab and poly-
clonal depleting induction therapy was made.
Three RCTs compared alemtuzumab with IFN-b-1a in
RRMS. In both the phase II (CAMMS223) and III trials
(CARE-MSI and CARE-MS-II), malignancy was not more
frequent after alemtuzumab compared with IFN-b-1a
[47, 48, 91]. In the CAMMS223 trial, malignancy was
observed in 2.8% of patients treated with alemtuzumab (one
patient with cervical cancer and one patient with breast
cancer) and 0.9% of patients taking IFN-b-1a (colon cancer)
after a follow-up of 3 years. In the extension part of this trial,
one patient in the alemtuzumab group died of sepsis fol-
lowing chemotherapy for Burkitt’s lymphoma [91]. In
CARE-MSI, two patients (0.5%) in the alemtuzumab group
developed thyroid papillary carcinoma. It is not clear whe-
ther these cases were induced by alemtuzumab or were an
incidental finding on ultrasound investigation of patients
with thyroid dysfunction after screening. No patients in the
IFN-b-1a group developed a malignancy [47]. In CARE-
MSII, malignancy rates for alemtuzumab- vs. IFN-b-1a-
treated patients were 0.6% vs. 1.5%, respectively, after
24 months of follow-up. These malignancies included one
case of papillary thyroid cancer, basal cell carcinoma (two
patients), cervical cancer (one patient), and colon cancer
(one patient) in the alemtuzumab-treated group. In the IFN-
b-1a-treated group, two malignancies were observed (one
patient with a basal cell carcinoma and one case of acute
myeloid leukemia) [48]. No further malignancies were
observed in the long-term open-label follow-up (median
7 years, range 33–144 months) [92].
Occurrence of EBV-positive large-cell lymphoma has
been described after administration of alemtuzumab in
patients with CLL. In a study to investigate the efficacy
and safety of alemtuzumab in patients with CLL with
residual disease, 3 of 41 patients developed EBV-posi-
tive large-cell lymphoma. Two of three patients had
spontaneous resolution without therapy and one patient
was treated with immunoglobulins and anti-viral medi-
cation [93]. A case report described the development of
an EBV-positive lymphoma in an 80-year-old patient
with CLL treated with chemotherapy and alemtuzumab
[94].
In conclusion, alemtuzumab results in an increased risk
of malignancy as compared with no induction therapy in
kidney transplantation. In contrast, no increased risk of
malignancy was associated with the use of alemtuzumab in
patients with MS when compared with IFN-b-1a.
7.4 Autoimmunity
Secondary autoimmune events have been reported after
alemtuzumab treatment. Interleukin-21 seems to play a role
in the development of this autoimmunity. Interleukin-21 is
involved in the proliferation of cytotoxic T lymphocytes,
the inhibition of regulatory T lymphocytes, and the dif-
ferentiation of B lymphocytes into antibody-producing
plasma cells [95]. Pre-treatment levels of IL-21 in patients
with MS were twofold higher in patients developing
autoimmunity after alemtuzumab treatment compared with
patients without autoimmunity [96].
Most commonly, the thyroid gland is affected.
Autoimmune thyroid disorders, especially hypothyroidism
and hyperthyroidism (Graves’ disease) tend to occur
between 6 and 61 months, peaking in the third year post-
treatment in patients with MS. In kidney transplantation,
Graves’ disease has also been observed after alem-
tuzumab administration [97]. The total incidence of thy-
roid events, described in CAMMS223, CARE-MSI, and
CARE-MSII, ranged between 16 and 30% [47, 48]. In the
patients treated with IFN-b-1a, the incidence of thyroid
events was 3–6%. It is advised that thyroid function tests
should be obtained prior to initiation of treatment and
tested on a regular basis until 48 months after the last
infusion [34].
Immune thrombocytopenia (idiopathic thrombocy-
topenic purpura) as a side effect of alemtuzumab treatment
was first described in the CAMMS223 study. A patient
presented with intracranial hemorrhage and died. The
incidence of idiopathic thrombocytopenic purpura was
1–2% in the CAMMS223 and CARE-MS studies
[47, 48, 91]. Furthermore, four cases of glomerulopathy
(0.3%) were described after alemtuzumab treatment in the
CAMMS223, CARE-MSI, and CARE-MSII trials. Two
patients developed anti-glomerular basement membrane
disease and two patients developed membranous
glomerulopathy. The onset of kidney disease ranged from 4
to 39 months after alemtuzumab administration
[47, 48, 91]. One case of Guillain–Barre syndrome was
reported in a patient treated with alemtuzumab because of a
T lymphocyte prolymphocytic leukemia [98].
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7.5 Fertility and Pregnancy
Alemtuzumab has been assigned to pregnancy category C
by the Food and Drug Administration, meaning that animal
production studies have shown an adverse effect on preg-
nancy outcomes but that no adequate studies have been
performed in humans [34]. Immunoglobulin G molecules,
such as alemtuzumab, are known to cross the placental
barrier and may potentially affect the fetus.
Sixmonths after delivery, concentrations of infliximab and
adalimumab can be detected in the baby [99]. The adminis-
tration of live vaccines (such as Bacillus Calmette-Guerin,
rotavirus, varicella zoster,mumps,measles, and rubella) in the
first 6 months after delivery to babies of mothers treated with
infliximab can be life threatening [100]. It is not known
whether alemtuzumab can cause fetal harm when adminis-
tered to pregnant women or whether it can affect reproductive
capacity. In the Cambridge long-term follow-up study of MS
patients, a total of 15 babies were born to 12 women treated
with alemtuzumab after a median interval from most recent
treatment of 26 months (range 13–86 months). All deliveries
and births were uncomplicated [92].
CD52 is expressed in the male reproductive system, includ-
ing the epididymis, vas deferens, seminal vesicles, and mature
spermatocytes [101]. Although CD52 antibodies agglutinate
and inactivate sperm in vitro, reproductive problems have not
been reported following therapy with alemtuzumab, although
available data are limited.A long-term follow-up study reported
six male individuals fathering seven live births, a median of
14 months (range 8–44 months) from most recent treatment to
conception [92]. Another (sub)study (n = 13) showed that at
baseline, and 1, 3, and 6 months post-alemtuzumab treatment,
there was no evidence of aspermia, azoospermia, motility dis-
orders, or depressed sperm counts [102].
It is unknown if alemtuzumab is excreted in human
breast milk, but it has been detected in the milk of lactating
mice. Therefore, breastfeeding should be discouraged to
women for at least 4 months following treatment [34].
8 Summary and Future Directions
Alemtuzumab is frequently used off-label in kidney trans-
plantation as induction therapy and less frequently as anti-
rejection therapy. No pharmacokinetic studies have been
performed in SOT recipients, probably because alem-
tuzumab has never been registered for this indication. Most
pharmacokinetic and pharmacodynamic studies have been
performed in patients with CLL and MS. However, the
pharmacokinetics of alemtuzumab in the latter two patient
populations may be very much different from SOT recipi-
ents. The alemtuzumab dose used in induction and anti-re-
jection therapy (30 mg one to two times) is not based on
formal dose-finding studies in SOT recipients, but is based
on experience in CLL and MS. The duration of depletion of
immune cells of the innate and the adaptive immune system
is much longer after alemtuzumab treatment compared with
rATG [103]. It may therefore be possible that lower doses of
alemtuzumab will result in the same effect on graft survival,
though with less toxicity. Subcutaneous administration
showed the same outcomes compared with intravenous
administration, but with less adverse events, although anti-
alemtuzumab antibody formation may be more frequent.
Induction therapy with alemtuzumab in kidney transplan-
tation shows comparable results in terms of graft and patient
survival as compared with basiliximab and rATG. However,
induction therapy with alemtuzumab is more effective in
preventingacute rejection as comparedwith induction therapy
with basiliximab.Results are comparable to induction therapy
with rATG. The use of alemtuzumab induction therapy may
facilitate minimization of the exposure to nephrotoxic
immunosuppressive drugs, which may possibly lead to better
long-term graft survival. Alemtuzumab used as anti-rejection
therapy has shown some promising results. Replacement of
rATG by alemtuzumab for this indication could lead to less
infusion-related adverse events, shorter hospital stay, and a
reduction in costs. However, long-term adverse events such as
infection, autoimmunity, malignancies, and a higher fre-
quency of ABMR may be more frequent among alem-
tuzumab-treated patients compared with rATG.
Although alemtuzumab is used off-label in kidney
transplantation, it can be an additional treatment option to
the drugs now used as induction or anti-rejection therapy.
We should start the discussion with a pharmaceutical
company to expand the indication for alemtuzumab to
SOT, and thus more clinical studies can be performed.
There is an unmet need to optimize alemtuzumab dosing in
patients undergoing SOT and we believe dose-finding
studies are needed. Furthermore, RCTs are required to
compare the effectiveness and long-term results of alem-
tuzumab with rATG for the treatment of acute rejection.
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